A5086969450- CAR-T cell therapy research
- Lymphoma Diagnosis and Treatment
- Virus-based gene therapy research
- Immunotherapy and Immune Responses
- Acute Lymphoblastic Leukemia research
- Polyomavirus and related diseases
- CNS Lymphoma Diagnosis and Treatment
- Cytomegalovirus and herpesvirus research
- Immune Cell Function and Interaction
- Parvovirus B19 Infection Studies
- Pancreatic and Hepatic Oncology Research
- Radiomics and Machine Learning in Medical Imaging
- Hematopoietic Stem Cell Transplantation
- Cancer Immunotherapy and Biomarkers
- Neuroblastoma Research and Treatments
- Chronic Lymphocytic Leukemia Research
- Lung Cancer Treatments and Mutations
- Viral-associated cancers and disorders
- Organ and Tissue Transplantation Research
- Complement system in diseases
- Intestinal Malrotation and Obstruction Disorders
- Oral health in cancer treatment
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Cancer therapeutics and mechanisms
- Healthcare and Venom Research
Children's National
2014-2023
George Washington University
2017-2023
Center for Cancer and Blood Disorders
2019-2021
George Washington University Hospital
2020
National Hospital
2020
National Cancer Institute
2011-2013
National Institutes of Health
2012-2013
Center for Cancer Research
2012-2013
Vanderbilt University
2013
East Carolina University
2013
Summary Treatment with dose‐adjusted EPOCH (etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone) chemotherapy and rituximab ( DA ‐ ‐R) has become the standard of care for primary mediastinal B‐cell lymphoma PMBCL ) at many institutions despite limited data in multi‐centre setting. We report a large, retrospective analysis children adults treated ‐R to characterize outcomes evaluate prognostic factors. assessed 156 patients across 24 academic centres, including 38 118 adults....
Patients with hematologic malignancies relapsing after allogeneic blood or marrow transplantation (BMT) have limited response to conventional salvage therapies, an expected 1-year overall survival (OS) of <20%. We evaluated the safety and clinical outcomes following administration a novel T-cell therapeutic targeting 3 tumor-associated antigens (TAA-T) in patients acute leukemia who relapsed were at high risk relapse BMT. Lymphocytes obtained from BMT donor manufactured target TAAs WT1,...
Background Immunocompromised patients are at increased risk of SARS-CoV-2 infections. Patients undergoing chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory B-cell malignancies uniquely immunosuppressed due to CAR T-mediated aplasia (BCA). While mortality rates 33%–40% reported in adult recipients, outcomes pediatric and young recipients limited. Methods We created an international retrospective registry T aged 0–30 years infected with within 2 months prior or any time...
Background Despite high cure rates for pediatric B-lineage acute lymphoblastic leukemia (B-ALL), short-term and long-term toxicities chemoresistance are shortcomings of standard chemotherapy. Immunotherapy chemoimmunotherapy based on monoclonal antibodies (mAbs) that target cell surface antigens with restricted expression in B-ALL may offer the potential to reduce prevent or overcome chemoresistance. The receptor tyrosine kinase ROR1 has emerged as a candidate mAb targeting select B-cell...
Umbilical cord blood (CB) has emerged as an effective alternative donor source for hematopoietic stem cell transplantation. Despite this success, the prolonged duration of immune suppression following CB transplantation and naiveté T cells leave patients susceptible to viral infections. Adoptive transfer ex vivo-expanded virus-specific from is both feasible safe. However, manufacturing process these complicated, lengthy, labor-intensive. We have now developed a simplified method manufacture...
Abstract Adoptive transfer of virus-specific T cells (VSTs) has been shown to be safe and effective in stem cell transplant recipients. However, the lack virus-experienced donor cord blood (CB) prevented development ex vivo expanded donor-derived VSTs for recipients this source. Here we evaluated feasibility safety expansion CB from 20% fraction unit pediatric patients receiving a single (CBT). In 2 clinical trials conducted at separate sites, manufactured CB-derived multivirus-specific...
Despite advances in immunotherapeutic strategies for neuroblastoma (NBL), relapse remains a significant cause of mortality high risk patients. The discovery novel tumor associated antigens to improve efficacy and minimize the toxicities immunotherapy is therefore warranted.
Key Points Children with PCNSL and no immunodeficiency have a good outcome when treated by histological subtype–driven radiation-free protocol. New treatment guidelines are needed for in children adolescents an underlying immunodeficiency.
The synovial sarcoma X breakpoint 2 (SSX2) belongs to a multigene family of cancer-testis antigens and can be found overexpressed in multiple malignancies. Its restricted expression immune-privileged normal tissues suggest that SSX2 may relevant target antigen for chimeric receptor (CAR) therapy. We have developed T cell (TCR)-like antibody (Fab/3) binds peptide 41-49 (KASEKIFYV) the context HLA-A∗-0201. sequence Fab/3 was utilized engineer CAR with CD3 zeta intra-cellular domain along...
BK virus (BKV)-hemorrhagic cystitis (HC) is a well-known and rarely fatal complication of hematopoietic stem cell transplantation (HSCT). Treatment for BKV-HC limited, but virus-specific T-cells (VST) represent promising therapeutic option feasible use posttransplant. We report on the case 16-year-old male with dedicator cytokinesis 8 (DOCK8) deficiency who underwent haploidentical HSCT complicated by severe BKV-HC, catastrophic renal hemorrhage, VST-associated cytokine release syndrome...
Hodgkin lymphoma (HL) Reed Sternberg cells express tumor-associated antigens (TAA) that are potential targets for cellular therapies. We recently demonstrated TAA-specific T (TAA-Ts) targeting WT1, PRAME, and Survivin were safe associated with prolonged time to progression in solid tumors. Hence, we evaluated whether TAA-Ts when given alone or nivolumab could elicit antitumor effects vivo patients relapsed/refractory (r/r) HL. Ten infused (8 autologous 2 allogeneic) active HL (n = 8) as...
The objective of this study was to evaluate pretransplant sinus computed tomography (CT) as predictor post-hematopoietic stem cell transplant sinusitis.We evaluated and posttransplant CT findings in 100 children using the Lund-Mackay system "common-practice" radiology reporting correlated these with presence acute sinusitis.Fourteen percent patients normal screening developed sinusitis, compared 23% radiographic abnormalities 22% clinical sinusitis alone, not statistically significant....
REVIEW article Front. Oncol., 01 July 2013Sec. Pediatric Oncology Volume 3 - 2013 | https://doi.org/10.3389/fonc.2013.00166
Outcomes for children and adolescents with relapsed refractory Hodgkin lymphoma (HL) are poor, ∼50% of patients experiencing a subsequent relapse. The anti-CD30 antibody-drug conjugate brentuximab vedotin improved progression-free survival (PFS) when used as consolidation after autologous stem cell transplantation (ASCT) in adults high-risk relapsed/refractory HL. Data on consolidative therapy ASCT pediatric HL extremely limited, data only 11 reported the literature. We performed...
Iatrogenic immunodeficiency-associated lymphoproliferative disorders (LPDs) are a group of lymphoid proliferations or lymphomas that well known to be associated with an immunosuppressed state. These most commonly occur following hematopoietic solid organ transplantation (called post-transplant PTLD), but cases have also been described during the treatment autoimmune and rheumatologic by immunosuppressive immunomodulatory medications. strongly infection Epstein-Barr virus (EBV) as result...
Introduction Among patients with high-risk cHL initial cure rates are suboptimal and rely on high cumulative doses of alkylating agents, anthracyclines radiation therapy (RT). Our overarching goal is to improve disease control minimize treatment burden by incorporating the targeted antibody drug conjugate Bv into COG legacy chemotherapy backbone, thus facilitating omission bleomycin reduction RT fields.